What Rubió does

Laboratorios Rubió is a privately-held Spanish pharmaceutical company founded in 1968 and headquartered in Castellbisbal, Barcelona. The company manufactures and commercializes licensed pharmaceutical products across multiple therapeutic areas — including ADHD (Rubifen, Rubifen Prolong, Rubicrono, Atamax), rheumatology and pain (Dolquine, Naprosyn, Antalgin), osteoporosis (Bonviva, Soludronate, Rocaltrol, Mastical D), nephrology (Fosquel, Resincalcio, Resincolestiramina), urology (Cystistat), andrology (Testogel), gynecology (Utrogestan), and adjuvant therapies — alongside nutritional supplements (the Profertil fertility range), medical devices (Gelsectan, Cicatridina, Suplasyn), and proprietary in vitro diagnostics (OWLiver for MASLD/MASH, Liposcale for advanced lipoprotein profiling). Manufacturing is centered on a 2,900 m² GMP-compliant plant exceeding 10 million finished units annually, with a multi-year expansion to nearly double capacity underway.

Rubió operates four business areas — Pharmaceuticals, OTC Nutraceuticals, Metabolomics, and Diagnostics — and earns revenue primarily through unit-pricing model sales of prescription and OTC products in Spain and through licensing and distribution arrangements with 80+ strategic partners across more than 70 countries. The pricing across the portfolio spans from budget generics (Rubifen 5mg at €2.42) to specialized treatments (Fosquel 2.4g at €194.70), with most products reimbursed through Spanish Social Security. Distribution outside Spain relies on partner-channel and licensing-out agreements, plus a dedicated U.S. joint venture (CIMA Sciences) for the OWLiver diagnostic. Vertically integrated capabilities include the in-house metabolomics platform (LC/MS and NMR) developed through the 2022 acquisition of Rubió Metabolomics / OWL Metabolomics, supporting both proprietary diagnostic products and third-party R&D services.

The customer base comprises healthcare professionals, hospitals, pharmacies, and patients across the 70+ countries served, with no single named customer or region dominating disclosed revenue. Recent strategic moves include acquisitions of Fisiopharma (2021), Rubió Metabolomics (2022), Rubió Nutraceuticals Italy (2023), and Nutribrain (2024), alongside the founding of the CIMA Sciences joint venture and an active Digital Health Startup Program targeting urology, rheumatology, CNS, nephrology, and gastroenterology startups. FY2024 revenue reached €181M (+38.23% YoY), with 284 employees across Spain and Italy and the first disclosed external financing (€4.65M from ICF) recorded in July 2025.

Name

Rubió

Legal name

LABORATORIOS RUBIÓ, SA

Website

https://laboratoriosrubio.com

Company type

Private

Founded year

1968

Operating status

Operating

Headcount range

101–250 employees

Short description

Laboratorios Rubió is a private Spanish pharmaceutical company founded in 1968 that manufactures and distributes prescription medicines, nutraceuticals, medical devices, and proprietary diagnostic tests (OWLiver, Liposcale) through direct sales in Spain and 80+ partners across 70+ countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals and In Vitro Diagnostics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin) (AFAJAKAK)

Keywords

• Pharmaceutical manufacturing
• In vitro diagnostics
• Nutraceutical supplements
• Metabolomics testing
• Specialty generic medicines

Headquarters

HQ city

Castellbisbal

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Manufacturing and sales of established medicines with strong reputation, introducing new products annually through proprietary R&D and third-party alliances. Focus on therapeutic areas including Rheumatology, Nephrology, Urology, CNS, and others.
2. Diagnostic Products: In vitro diagnostic tests including OWLiver for non-invasive liver disease diagnosis and Liposcale for advanced lipoprotein analysis for cardiovascular risk assessment.
3. OTC Nutraceuticals: Complete formulas for food supplements targeting osteoarticular and muscular health, distributed through Fisiopharma and Rubió Nutraceuticals.
4. Licensing and Distribution: Commercialization and distribution agreements for third-party pharmaceutical products in Spain as local representative, including products from Atnahs Pharma, Besins Healthcare, and Lenus Pharma.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Laboratorios Rubió manufactures and commercializes specialty pharmaceutical products (notably methylphenidate-based ADHD treatments, hydroxychloroquine, naproxen, sevelamer, ibandronic acid, alendronic acid, testosterone, calcitriol), licensed nutritional supplements (Profertil fertility line, Fisiopharma osteoarticular range, Nutribrain cognitive health), medical devices (Gelsectan for IBS, Cicatridina, Suplasyn for joints, Actim diagnostics), and proprietary in vitro diagnostics (OWLiver for MASLD, Liposcale for lipoprotein profiling). Production runs at a GMP-certified Castellbisbal plant, with commercial reach through Spanish wholesalers and 80+ international strategic partners across 70+ countries.

Product overview

Laboratorios Rubió is a Spanish pharmaceutical company with over 50 years of experience operating through four main business areas: Pharmaceuticals, OTC Nutraceuticals, Metabolomics, and Diagnostics. The company manufactures and commercializes a broad portfolio of licensed pharmaceutical products (including Rubifen®, Rubicrono®, Rubifen Prolong® for ADHD; Dolquine® for rheumatoid arthritis and malaria; Naprosyn®/Antalgin® for pain/inflammation; Bonviva®/Soludronate® for osteoporosis; Rocaltrol® for bone disorders; Testogel® for testosterone replacement; and kidney-related products like Fosquel®, Resincalcio®, Resincolestiramina®), licensed nutritional supplements (Profertil® family for fertility/reproductive health), licensed medical devices (Gelsectan® for IBS, Cicatridina® for wound healing, Suplasyn® for joints), and proprietary diagnostic products (OWLiver® for MASLD diagnosis via metabolomics, Liposcale® for advanced lipoprotein profiling). The company operates its own 2,900m² GMP-certified manufacturing plant in Castellbisbal, Barcelona with capacity exceeding 10 million finished units annually.

Differentiator

Problem solved

Functional benefit

Brands

• Campus Rubió: Educational and training platform of Laboratorios Rubió offering courses, conferences, and events for professional development.
• Digital Health Startup Program

Products and services

• Utrogestan Vaginal soft capsules containing micronized progesterone, indicated for luteal phase supplementation during assisted reproduction techniques (ART) and prevention of preterm birth in women with short cervical length. Sold under license in Spain.
• Rubifen Prolong Modified-release hard capsules containing methylphenidate (50% immediate release, 50% extended release), indicated for ADHD treatment in children from 6 years, adolescents, and adults.
• Rubifen Tablets containing methylphenidate hydrochloride, indicated as part of a comprehensive ADHD treatment program in children from 6 years under specialist supervision.
• Rubicrono Extended-release tablets containing methylphenidate hydrochloride, indicated as part of a comprehensive ADHD treatment program in children from 6 years.
• Atamax Hard capsules containing atomoxetine hydrochloride, indicated for ADHD treatment in children from 6 years, adolescents, and adults as part of a complete treatment program.
• Naprosyn 500 mg Tablets containing naproxen 500 mg, indicated for treatment of mild to moderate pain, symptomatic treatment of rheumatoid arthritis, osteoarthritis, acute gout episodes, ankylosing spondylitis, primary dysmenorrhea, acute migraine attacks, and menorrhagia.
• Antalgin Film-coated tablets containing naproxen sodium 550 mg, indicated for mild to moderate pain, symptomatic treatment of rheumatoid arthritis, osteoarthritis, acute gout, dysmenorrhea, migraine attacks, and menorrhagia.
• Dolquine Film-coated tablets containing hydroxychloroquine sulfate, indicated for treatment of acute or chronic rheumatoid arthritis, systemic and discoid lupus erythematosus, and prophylaxis and treatment of uncomplicated malaria.
• Bonviva 150 mg Film-coated tablets containing ibandronic acid 150 mg, indicated for treatment of osteoporosis in postmenopausal women at high risk of fractures.
• Soludronate Weekly 70 mg Oral solution containing alendronic acid 70 mg, indicated for treatment of postmenopausal osteoporosis, reducing the risk of vertebral and hip fractures.
• Fosquel Tablets and oral powder for suspension containing sevelamer carbonate, indicated for control of hyperphosphatemia in adult patients on hemodialysis or peritoneal dialysis and in chronic kidney disease patients.
• Resincolestiramina Oral powder for suspension containing calcium polystyrene sulfonate, indicated for treatment of hypercholesterolemia, pruritus associated with partial biliary obstruction, and bile acid malabsorption.
• Resincalcio Oral powder for suspension containing calcium polystyrene sulfonate, indicated for treatment and prevention of hyperkalemia.
• Cystistat Sterile solution of sodium hyaluronate for temporary replacement of the glycosaminoglycan (GAG) layer of the urinary bladder, indicated for radiation cystitis, infectious cystitis, interstitial cystitis, and hemorrhagic cystitis.
• Testogel 50 mg Transdermal gel containing testosterone 50 mg per sachet, indicated for testosterone replacement therapy in adults with male hypogonadism.
• Rocaltrol Soft capsules containing calcitriol (0.25 or 0.50 micrograms), indicated for renal osteodystrophy, post-surgical and idiopathic hypoparathyroidism, pseudo hypoparathyroidism, vitamin D-dependent rickets, and osteoporosis.
• Mastical D Chewable tablets containing calcium and vitamin D3 in various dosages (500 mg/400 UI, 500 mg/800 UI, 500 mg/1000 UI), indicated for prevention and treatment of calcium and vitamin D deficiency in adults at associated risk.
• Profertil Nutritional supplement containing L-carnitine, L-arginine, coenzyme Q10, glutathione, vitamins and minerals, contributing to normal fertility function, reproduction, and spermatogenesis in men.
• Profertil female Nutritional supplement containing folic acid, selenium, vitamin E, coenzyme Q10, green tea extract catechins, licorice extract glycrrhizin, and omega-3 fatty acids, supporting women who want to conceive.
• Profertil Inositol Nutritional supplement containing myo-inositol, vitamin B6, folic acid (folate), and Quatrefolic, supporting physiological functions and homocysteine metabolism.
• OWLiver Non-invasive serum-based metabolomic diagnostic test using lipidomic analysis via UHPLC-MS to diagnose and monitor MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) across all disease stages. CE-marked under Directive 98/79/EC.
• Liposcale Advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy that comprehensively characterizes lipoprotein profiles including size, concentration, and lipid composition of VLDL, LDL, and HDL subclasses.
• Gelsectan Medical device containing xyloglucan for restoring intestinal function in patients with Irritable Bowel Syndrome (IBS) symptoms including chronic diarrhea, abdominal distension, pain, and flatulence.
• Cicatridina Medical device containing sodium hyaluronate for vaginal and anorectal healing, indicated for atrophic and dystrophic repair processes including postpartum recovery, gynecological surgeries, hemorrhoids, and anal fissures.
• Suplasyn Medical device containing sodium hyaluronate for joint supplementation.
• Actim Partus Diagnostic medical device for parturition detection.
• Actim Prom Diagnostic medical device for premature rupture of membranes detection.

Quantifiable outcome

• 38.23% revenue growth in 2024, reaching €181 million
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Rubió Group (OWL Metabolomics)coreStrategic or Co-development Partner · 14 June 2023Rubió Metabolomics joined the Rubió Group as a strategic alliance for advancing metabolomics and personalized medicine. This acquisition enhances capacity to develop diagnostic products and research services, leveraging synergies with Rubió Group's existing pharmaceutical expertise.
• CIMA SciencescoreStrategic or Co-development PartnerJoint venture founded in 2022 in the United States for international commercialization of OWLiver, the leading non-invasive diagnostic test for MASLD/MASH. CIMA Sciences consolidates US market expansion and strengthens internationalization of OWLiver.
• Biosfer TeslabcoreStrategic or Co-development PartnerSpin-off from Rovira i Virgili University (URV) and Pere Virgili Health Research Institute (IISPV), partially owned by Laboratorios Rubió. Specializes in development of in vitro diagnostic tests for cardiovascular risk evaluation in high-risk patients. Developed Liposcale technology.
• INCLIVAminorStrategic or Co-development PartnerCollaboration agreement with INCLIVA to promote biomedical research jointly.
• CetaceaminorOthersCollaboration with Cetacea for marine biodiversity preservation and sustainable future initiatives.
• 80+ International Strategic PartnerscoreChannel Partner/ Reseller/ DistributorNetwork of over 80 strategic partners managing commercial relationships and distribution agreements in more than 70 countries, focusing on key therapeutic areas, R&D, and health sector advancements.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Faes Farma: Spanish mid-cap pharmaceutical company with a similar multi-therapeutic portfolio (rheumatology, dermatology, OTC) and a recent track record of growth through acquisitions and international expansion, directly comparable in scale and geographic mix.
• Laboratorios Farmaceuticos Rovi (ROVI): Spanish-listed pharmaceutical manufacturer of similar size with own manufacturing, specialty therapeutics, and a focus on international licensing; directly comparable business model of branded-generic specialty pharma with export-driven growth.
• Laboratorios Esteve: Family-controlled Spanish pharma with parallel portfolio spread across multiple therapeutic areas, generics and licensing activities, and a developing international and nutraceuticals footprint — closely analogous in scope and ownership structure.
• KRKA: Slovenian generics and specialty pharma with own manufacturing, broad therapeutic spread, and export-led growth exceeding 90% of sales — virtually the same mid-cap European generics+specialty playbook as Rubió.

Broad incumbents

• Almirall: Spain's largest listed dermatology-focused pharma, but with broad specialty prescription products and a similar GMP manufacturing footprint; broader therapeutic reach but overlapping in established-molecule European distribution.
• Stada Arzneimittel: Major European generics and specialty pharma group with broad therapeutic areas and a multi-country partner distribution model that closely mirrors Rubió's 80-partner, 70+ country positioning.
• Recordati: Italian mid-cap specialty pharma focused on rare diseases, urology, and gastroenterology; operates in adjacent therapeutic categories to Rubió and shares the Mediterranean European specialty pharma archetype.
• Menarini Group: Italian private/family-owned pharma with extensive branded prescription and OTC portfolio across Europe — comparable governance model (private/family), portfolio breadth, and Mediterranean European operating footprint.

Regional players

• Casen Recordati: Spanish subsidiary of Italian Recordati, focused on branded specialty pharma across urology, endocrinology, and gastroenterology — significant portfolio overlap with Rubió in Spain, particularly in urology/cystitis and gastroenterology.

Emerging players

• Polpharma: Polish pharma with a broad generics/specialty portfolio and export focus — analogous mid-size European player with established-molecule focus and ongoing expansion beyond home market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/labrubio
• YouTubeyoutube.com/user/LaboratoriosRubio
• LinkedInes.linkedin.com/company/laboratorios-rubi%C3%B3
• Facebookfacebook.com/Laboratorios-Rubio-241990249484291

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rubió